Novel Vpx virus-like particles to improve cytarabine treatment response against acute myeloid leukemia
Clinical and Experimental Medicine · 2024
DOI: 10.1007/s10238-024-01425-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Medicine, 2024. Verfasst von Ramya Nair und 12 weiteren Autor:innen. Beteiligte Einrichtung: Max Von Pettenkofer Institute and Gene Center, Virology, National Reference Center for Retroviruses, Faculty of Medicine, LMU München, Feodor-Lynen-S…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Cytarabine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wilhelm Sander-Stiftung, Fundação para a Ciência e Tecnologia, Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Knowledge of the molecular pathogenesis of acute myeloid leukemia has advanced in recent years. Despite novel treatment options, acute myeloid leukemia remains a survival challenge for elderly patients. We have recently shown that the triphosphohydrolase SAMHD1 is one of the factors determining resistance to Ara-C treatment. Here, we designed and tested novel and simpler virus-like particles incorporating the lentiviral protein Vpx to efficiently and transiently degrade SAMHD1 and increase the efficacy of Ara-C treatment. The addition of minute amounts of lentiviral Rev protein during production enhanced the generation of virus-like particles. In addition, we found that our 2nd generation of virus-like particles efficiently targeted and degraded SAMHD1 in AML cell lines with high levels of SAMHD1, thereby increasing Ara-CTP levels and response to Ara-C treatment. Primary AML blasts were generally less responsive to VLP treatment. In summary, we have been able to generate novel and simpler virus-like particles that can efficiently deliver Vpx to target cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Max Von Pettenkofer Institute and Gene Center, Virology, National Reference Center for Retroviruses, Faculty of Medicine, LMU München, Feodor-Lynen-Str. 23, 81377, Munich, Germany.
- Department of Medicine III, University Hospital, LMU, Munich, Germany.
- Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany.
- Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, 60596, Frankfurt Am Main, Germany.
- CIBIO-InBIO, Research Center in Biodiversity and Genetic Resources, University of Porto, 4485-661, Vairão, Portugal.
- Department of Biology, Faculty of Sciences, University of Porto, 4169-007, Porto, Portugal.
Förderung
- Wilhelm Sander-Stiftung
- Fundação para a Ciência e Tecnologia
- Deutsche Forschungsgemeinschaft
- Studienstiftung des deutschen Volkes
- Joachim Herz Foundation
- Bavarian Elite Graduate School “i-target”
- Fraunhofer Cluster of Excellence for Immune mediated Diseases
- Ludwig-Maximilians-Universität München
Zitieren
APA
Nair, R., Salinas-Illarena, A., Sponheimer, M., Wullkopf, I., Schreiber, Y., Côrte-Real, J. V., Del Pozo Ben, A., Marterer, H., Thomas, D., Geisslinger, G., Cinatl, J., Subklewe, M., & Baldauf, H. M. (2024). Novel Vpx virus-like particles to improve cytarabine treatment response against acute myeloid leukemia. Clinical and Experimental Medicine. https://doi.org/10.1007/s10238-024-01425-w
Vancouver
Nair R, Salinas-Illarena A, Sponheimer M, Wullkopf I, Schreiber Y, Côrte-Real JV, et al. Novel Vpx virus-like particles to improve cytarabine treatment response against acute myeloid leukemia. Clinical and Experimental Medicine. 2024. doi:10.1007/s10238-024-01425-w
BibTeX
@article{Nair2024,
author = {Nair, Ramya and Salinas-Illarena, Alejandro and Sponheimer, Monika and Wullkopf, Inès and Schreiber, Yannick and Côrte-Real, João Vasco and Del Pozo Ben, Augusto and Marterer, Helena and Thomas, Dominique and Geisslinger, Gerd and Cinatl, Jindrich and Subklewe, Marion and Baldauf, Hanna-Mari},
title = {Novel Vpx virus-like particles to improve cytarabine treatment response against acute myeloid leukemia},
journal = {Clinical and Experimental Medicine},
year = {2024},
doi = {10.1007/s10238-024-01425-w}
}
EUVIMED